In a year in which regulators and drug companies gained familiarity with risk management strategies, the number of new drug approvals was similar to that in 2008.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. 2009 FDA drug approvals. Nat Rev Drug Discov 9, 89–92 (2010). https://doi.org/10.1038/nrd3101
Issue Date:
DOI: https://doi.org/10.1038/nrd3101
This article is cited by
-
Molecular modeling investigation of adsorption of Zolinza drug on surfaces of the B12N12 and Al12N12 nanocages
Structural Chemistry (2021)
-
Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives
Archives of Toxicology (2017)
-
Case Report: Artificial Elevation of Prothrombin Time by Telavancin
Clinical Orthopaedics & Related Research (2013)
-
Unraveling the autoimmune translational research process layer by layer
Nature Medicine (2012)
-
Systems-based approaches to cardiovascular disease
Nature Reviews Cardiology (2012)